Phase 3, 24 week, double-blind study to assess the efficacy and safety of a subcutaneous injection for adults with moderate-to-severe atopic dermatitis

(and Long-Term Extension Study)

Phase 3 multicenter open-label performance study with self-administered subcutaneous injection in adults with moderate-to-severe atopic dermatitis

Phase 3b double-blind, randomized, vehicle-controlled efficacy and safety study of cream in adults with moderate atopic dermatitis

Phase 3, double-blind, randomized efficacy and safety study of an oral agent in participants with moderate to severe hidradenitis suppurativa (and Long-Term Extension Study)

Phase 3, randomized, double-blind efficacy and safety study of an oral agent in subjects with moderate to severe HS who have failed anti-TNF therapy

Phase 3b, randomized, double-blind efficacy and safety study of a subcutaneous injection for the treatment of low BSA moderate plaque psoriasis with special site involvement

Phase 4 multicenter, randomized, open-label, efficacy assessor blinded study of an injectable compared to an oral agent for the treatment of adult subjects with moderate plaque psoriasis who are candidates for systemic therapy